Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its presentation at the Sidoti Investor Conference on August 17-18, 2022. The company focuses on developing innovative biopharmaceutical treatments aimed at improving patient quality of life. Hoth is dedicated to early-stage pharmaceutical research and collaborates with scientists and clinicians to explore impactful therapeutics. For more details on the conference, interested parties can visit the Sidoti website.

Hoth Therapeutics (NASDAQ: HOTH) announced promising results from a study of HT-ALZ, a treatment for Alzheimer's disease (AD), demonstrating significant cognitive improvements in behavioral tests after chronic dosing in a mouse model. Conducted in collaboration with Washington University, the study showed that after more than five weeks of treatment, HT-ALZ-treated mice exhibited notable enhancements compared to vehicle-treated controls. Future research will further explore the treatment's effects, including memory and anxiety, providing optimism for its potential in AD therapy.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) received a 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, giving the company until December 26, 2022, to regain compliance. This decision follows an earlier notification from Nasdaq regarding Hoth's non-compliance based on its stock performance over the previous 30 days. If the company achieves the bid price requirement for 10 consecutive business days during this period, Nasdaq will confirm compliance. Failure to do so may lead to potential delisting, though the company can appeal such a decision.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that it has received approval from the Bellberry Human Research Ethics Committee in Australia to proceed with the next phase of its BioLexa trial for Atopic Dermatitis patients. This approval marks a significant milestone in Hoth's clinical trial journey. BioLexa is a patented antimicrobial topical formulation designed to prevent Staphylococcal biofilm formation, which is critical for treating chronic infections that can lead to antibiotic resistance. The company aims to leverage this opportunity to enhance patient quality of life through innovative therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that its Annual Meeting of Shareholders, originally scheduled for June 15, 2022, has been adjourned until June 23, 2022, at 12:00 p.m. ET. This decision aims to allow additional time for proxy solicitation and to achieve a quorum for voting. The meeting will be conducted virtually. Shareholders of record as of April 25, 2022, are encouraged to vote their shares by 11:59 p.m. ET on June 22, 2022. No changes to the proposals for the meeting have been made.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an extension of its Sponsored Research Agreement with Washington University in St. Louis to further investigate HT-ALZ, a potential treatment for Alzheimer's disease. The ongoing research aims to establish a human equivalent dose for HT-ALZ, based on previous studies showing its ability to reduce amyloid β (Aβ) levels in mouse models. The study is led by Dr. Carla Yuede and Dr. John Cirrito, focusing on the effects of chronic administration on cognitive outcomes in Alzheimer’s models.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced preliminary findings from its Phase 1b clinical trial of BioLexa Lotion for mild to moderate atopic dermatitis. Conducted in Australia, the study showed some patients experienced improvement in symptoms across three efficacy endpoints: Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Investigator Global Assessment (IGA). No adverse events were reported during the dosing period. Full study results will be released later.

Hoth Therapeutics has introduced HT-TBI, a novel drug-device combination aimed at treating secondary brain injury related to ischemic strokes and traumatic brain injuries. This product offers point-of-care treatment options for patients and emergency responders, addressing significant delays in delivering care, which can worsen patient outcomes. Statistics reveal over 12.2 million new strokes occur annually, underscoring the urgency of timely intervention. HT-TBI represents Hoth's commitment to improving neurological health through innovative solutions.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully closed an underwritten public offering of 8,235,294 shares of common stock at a price of $0.85 per share, generating approximately $7.0 million in gross proceeds. The offering included a 45-day option for underwriters to purchase an additional 1,235,294 shares. Proceeds will be allocated for general corporate and working capital purposes. The offering was conducted under a shelf registration statement filed with the SEC.